Nurix Therapeutics, Inc. (NRIX)

Market Cap	1.40B
Revenue (ttm)	56.42M
Net Income (ttm)	-176.98M
Shares Out	70.84M
EPS (ttm)	-2.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,484,664
Open	19.90
Previous Close	20.04
Day's Range	19.66 - 20.61
52-Week Range	7.65 - 29.56
Beta	2.11
Analysts	Strong Buy
Price Target	30.29 (+52.75%)
Earnings Date	Feb 13, 2025

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 284
• Stock Exchange: NASDAQ
• Ticker Symbol: NRIX
• Website: https://www.nurixtx.com

Financial Performance

In 2023, Nurix Therapeutics's revenue was $76.99 million, an increase of 99.31% compared to the previous year's $38.63 million. Losses were -$143.95 million, -20.19% less than in 2022.

Analyst Forecast

According to 17 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price forecast is $30.29, which is an increase of 52.75% from the latest price.

Price Target

$30.29

(52.75% upside)

Analyst Consensus: Strong Buy